Tags
Language
Tags
March 2024
Su Mo Tu We Th Fr Sa
25 26 27 28 29 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31 1 2 3 4 5 6

Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products (Repost)

Posted By: tukotikko
Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products (Repost)

Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products By Terrence P. Tougas, Jolyon P. Mitchell, Svetlana A. Lyapustina
2013 | 433 Pages | ISBN: 1461462959 | PDF | 14 MB


The purpose of this publication is to introduce a new, simpler and more effective way in which to interpret pharmaceutical aerosol particle size data from orally inhaled products (OIPs). Currently, the compendial and regulatory requirements dictate the need for measurements by full resolution multi-stage cascade impactor (CI), a process that is demanding for the operator, time consuming, prone to experimental error, and challenging for method transfers from one laboratory to another. Furthermore, we shall show that the current practice of reducing information from mass-weighted aerodynamic particle size distribution (APSD) measurements through the use of CI stage groupings is not the most effective decision-making tool for OIP quality control (QC) in comparison with newly introduced, mutually-independent efficient data analysis (EDA) metrics that can be derived either from full resolution or abbreviated impactor measurements (AIM).